Arbutus Biopharma Corp Debt Securities, Available-for-sale
Arbutus Biopharma Corp (ABUS) had Debt Securities, Available-for-sale of $73.45 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale $73.45M.
- 2026-03-31: Debt Securities, Available-for-sale $71.52M.
- 2025-12-31: Debt Securities, Available-for-sale $73.46M.
- 2025-09-30: Debt Securities, Available-for-sale $71.29M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $73.45M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $71.52M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $73.46M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $71.29M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $60.68M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $75.63M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $86.29M 10-K · filed 2026-03-23 | |
| 2022-12-31 | $116.10M 10-K · filed 2023-03-02 | |
| 2022-09-30 | $110.70M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $102.90M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $84.10M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $46.00M 10-Q · filed 2022-11-09 | $81.72M 10-K · filed 2022-03-03 |
| 2021-09-30 | $43.50M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $47.40M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $52.54M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $71.02M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $21.40M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $36.50M 10-Q · filed 2020-08-07 | |
| 2019-12-31 | $59.03M 10-K · filed 2021-03-04 | $59.00M 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |